Roche has announced the launch of a massive AI factory, powered by NVIDIA’s cutting-edge technology, to significantly accelerate the development of new therapeutics and diagnostics solutions. This strategic collaboration expands Roche’s existing partnership with NVIDIA and positions the company to operate the pharmaceutical industry’s largest announced hybrid-cloud AI factory, boasting over 3,500 NVIDIA Blackwell GPUs. The new infrastructure, which includes an addition of 2,176 GPUs deployed across the United States and Europe, will embed AI across Roche’s entire value chain, from discovery and development to manufacturing and commercialization. The introduction of this expansive AI infrastructure signifies a critical step in Roche’s digital transformation and its commitment to advancing healthcare outcomes. By integrating NVIDIA’s powerful computing capabilities with Roche’s scientific expertise, the company aims to revolutionize how life-changing medicines and diagnostics are developed and delivered to patients. Wafaa Mamilli, Roche’s Chief Digital and Technology Officer, emphasized the critical role of time in healthcare, stating, “every day saved means a life-changing medicine or diagnostic reaches a patient sooner.” The AI factory combines world-class computing power with Roche’s scientific knowledge to embed AI across the entire value chain, transforming the delivery of next-generation medical solutions.
Revolutionizing Drug Discovery and Development
In research and development, Roche is leveraging NVIDIA’s BioNeMo platform to enhance its “Lab-in-the-Loop” approach. This integration connects biological and chemistry experiments directly with AI models, enabling scientists to test hypotheses at scale, accelerate progress, and achieve discoveries previously thought impossible. Aviv Regev, Executive Vice President and Head of Genentech Research and Early Development, highlighted how this expanded collaboration strengthens Roche’s leadership in AI-driven drug discovery. The company has already seen AI’s impact, with AI tools aiding in the design of specialized oncology treatment molecules 25% faster and with novel structures. Furthermore, AI has been instrumental in ensuring that new cancer treatments in human trials do not trigger adverse immune responses, significantly increasing their chances of success.
Enhancing Diagnostics and Manufacturing
Beyond drug discovery, Roche’s AI factory is poised to enhance its diagnostics business and manufacturing processes. For diagnostics, accelerated computing and NVIDIA Parabricks software are enabling deeper insights from vast datasets. In digital pathology, NVIDIA technologies are used to scan numerous images, identifying subtle disease patterns. For manufacturing, NVIDIA Omniverse libraries are powering digital twins – virtual replicas of production lines – allowing engineers to optimize processes and factory designs for greater efficiency. Additionally, Roche is employing NVIDIA NeMo Guardrails to ensure the safety and reliability of its healthcare-grade conversational AI tools, improving digital health applications.
